Skip to main content

Table 3 Adverse events (AEs) collected during the 12 weeks of erenumab therapy

From: MAB-MIG: registry of the spanish neurological society of erenumab for migraine prevention

AE

Absolute number and percentage

Constipation

16 (7.6%)

Flu-like symptoms

8 (3.8%)

Pruritus after injection

6 (2.8%)

Fatigue

5 (2.3%)

Dizziness

3 (1.4%)

Nausea after injection

3 (1.4%)

Upper respiratory tract infection

2 (0.9%)

Skin rash after injection

2 (0.9%)

Lymphadenopathy

1 (0.4%)

Serotoninergic syndrome

1 (0.4%)

Loss of sexual desire

1 (0.4%)

Melanoma

1 (0.4%)

Diarrhoea

1 (0.4%)

Myalgia

1 (0.4%)

Injection site pain

1 (0.4%)

Muscular spam

1 (0.4%)

Panic attack

1 (0.4%)

Palpitations

1 (0.4%)

Dehydration

1 (0.4%)

Hypermenorrhoea

1 (0.4%)

Death

0 (0%)

Total

57